Aav tbg cre

Manufactured by Addgene

AAV-TBG-Cre is an adeno-associated virus (AAV) vector that expresses the Cre recombinase enzyme under the control of the TBG (thyroxine-binding globulin) promoter. The core function of this product is to enable Cre-mediated recombination in target cells or tissues.

Automatically generated - may contain errors

Lab products found in correlation

Tamoxifen, by Research Diets (1 mentions) Tamoxifen, by Merck Group (1 mentions)

2 protocols using aav tbg cre

Liver-specific Nrf2 and Gclc Knockout Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animal studies were performed according to protocols approved by the University Committee on Animal Resources at the University of Rochester Medical Center. Gclc^f/f mice were generated as described^{30 (link)} and crossed with the Rosa26-CreERT2 mouse strain (Jackson Labs, #008463) or Nrf2^f/f mouse strain (Jackson Labs, #025433). All animals were aged for at least 12 weeks before being used in their respective experiments. Tamoxifen (Sigma Aldrich, T5648) was administered by intraperitoneal injection at 160 mg/kg once daily for five days. For liver-specific genetic deletions, mice were injected via the tail vein with 2.5×10¹¹ GC of AAV-TBG-Cre (Addgene, 107787-AAV8) in PBS. For high-fat diet experiments, mice were fed a 60 kcal% fat high-fat diet (Research Diets, D12451i) following either Tamoxifen or AAV-TBG-Cre injection for 2–3 weeks. Control mice were fed normal rodent chow (LabDiet, 5053).

Asantewaa G., Tuttle E.T., Ward N.P., Kang Y.P., Kim Y., Kavanagh M.E., Girnius N., Chen Y., Duncan R., Rodriguez K., Hecht F., Zocchi M., Smorodintsev-Schiller L., Scales T.Q., Taylor K., Alimohammadi F., Sechrist Z.R., Agostini-Vulaj D., Schafer X.L., Chang H., Smith Z., O’Connor T.N., Whelan S., Selfors L.M., Crowdis J., Gray G.K., Bronson R.T., Brenner D., Rufini A., Dirksen R.T., Hezel A.F., Huber A.R., Munger J., Cravatt B.F., Vasiliou V., Cole C.L., DeNicola G.M, & Harris I.S. (2023). Glutathione supports lipid abundance in vivo. bioRxiv.

+ Open protocol

+ Expand

Genetically Engineered Mouse Models of Liver Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animals used in this study were C57BL/6J background. The animal protocol (S09108) was approved by the IACUC at University of California San Diego. The SKO (Shp2^hep−/−) and BKO (B-catenin^hep−/−) mouse lines were generated using Albumin-Cre as previously described (Bard-Chapeau et al., 2006 (link)). The SBKO line was generated by breeding SKO and BKO mouse lines together, maintaining heterozygous expression of Albumin-cre. Tumor models were generated by hydrodynamic tail vein injection (HTVi) using a ratio of 10:1 for DNA plasmid to sleeping beauty transposase. For the Ras/Myc model, Ras and Myc were used at a ratio of 95:5 for a total 10 μg/ml. Plasmids (Bcat: PT3-EF1a-ΔN90-β-catenin; PT3-EF1a-C-Myc; PT/Caggs-Nras-V12, pCMV/SB11) were kindly provided by Dr. X Chen at University of California San Francisco. Plasmid PCKO-dnTCF7l2 was kindly provided by Dr. Gregory Lemke at Salk Institute for Biological Sciences (Vacik et al., 2011 (link)). PT3-EF1a-eGFP and PT3-EF1a-dnTCF7l2 were cloned for use. Plasmid DNAs were diluted in phosphate-buffered saline (PBS) and injected at 0.1 mL/g body weight through the tail vein in 4-6 s. AAV-TBG-GFP (Addgene; 105535) and AAV-TBG-Cre (Addgene; 107787) were purchased from Addgene and injected at the titer of 2 × 10¹¹ pfu/mouse.

Chen W.S., Liang Y., Zong M., Liu J.J., Kaneko K., Hanley K.L., Zhang K, & Feng G.S. (2021). Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment. Cell reports, 37(6), 109974.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!